Reviewed by Prof. Dr. Serdar Baki Albayrak, Neurosurgeon, Istanbul, Turkey.
The World Health Organization assigns every brain tumor a grade from 1 to 4. This grade reflects how aggressively the tumor behaves. Glioblastoma sits at Grade 4, therefore it represents the highest and most aggressive category.
This guide explains how that grading system works today. In addition, it covers what changed in the most recent WHO update and why grade shapes every later treatment decision. For a broader introduction to the disease, see our complete guide to glioblastoma. Higher grade also generally means faster symptom onset, a pattern our guide to glioblastoma symptoms and early warning signs explains in detail.
The WHO CNS Tumor Classification System
Pathologists worldwide use the WHO Classification of Tumors of the Central Nervous System to name and grade brain tumors consistently. The most recent major revision, known as WHO CNS5, changed grade numbering from Roman numerals to Arabic numerals. Consequently, what once appeared as Grade IV now appears as Grade 4 in current pathology reports.
More importantly, WHO CNS5 shifted grading practice in a meaningful way. Instead of relying on microscope appearance alone, it now combines traditional histology with molecular and genetic testing. Therefore, two tumors that look similar under a microscope can still receive different grades if their underlying genetics differ.
- WHO CNS4 (2016): introduced early molecular criteria while still using Roman numerals
- WHO CNS5 (2021): switched to Arabic numerals and expanded molecular criteria significantly
- Ongoing updates: continue to refine how specific mutations affect final grade
WHO Grades 1 Through 4 Explained
Grade reflects how fast a tumor grows and how likely it is to spread into nearby brain tissue. For example, lower grades generally behave less aggressively, while higher grades demand faster, more intensive treatment. The table below summarizes the key differences.
| WHO Grade | Typical Behavior | Example Tumor | General Treatment Approach |
|---|---|---|---|
| Grade 1 | Slow-growing, well-defined, often curable with surgery | Pilocytic astrocytoma | Surgical resection, often curative |
| Grade 2 | Slow-growing but diffusely infiltrative | Diffuse astrocytoma, IDH-mutant | Surgery plus monitoring or adjuvant therapy |
| Grade 3 | Anaplastic, actively dividing cells, higher recurrence risk | Anaplastic astrocytoma | Surgery, radiation, and chemotherapy |
| Grade 4 | Highly aggressive, necrosis, rapid growth | Glioblastoma, IDH-wildtype | Maximal safe resection, radiation, and temozolomide chemotherapy |
Our guide covering Grade 1 pilocytic astrocytoma illustrates, by contrast, how differently a low-grade tumor behaves compared with glioblastoma at the opposite end of this spectrum.
What Makes Glioblastoma a Grade 4 Tumor
Pathologists confirm Grade 4 status by identifying specific features under the microscope. These features distinguish glioblastoma from lower-grade astrocytomas that may otherwise look superficially similar in an early biopsy sample.
- Necrosis: areas of dead tumor tissue, often surrounded by densely packed tumor cells
- Microvascular proliferation: abnormal, rapidly forming blood vessels that feed the tumor
- High mitotic activity: a high rate of cell division visible under the microscope
- Marked nuclear atypia: abnormal-looking cell nuclei that indicate aggressive behavior
Historically, doctors called this tumor glioblastoma multiforme, since its microscopic appearance varied so widely from one area to another. Today, however, current WHO terminology simply uses glioblastoma, though the older name still appears often in older literature and patient materials.
How Pathologists Determine Grade From Tissue Samples
Grading never relies on imaging alone. Instead, a neuropathologist examines actual tumor tissue obtained during biopsy or surgery under a microscope, then confirms the findings with molecular laboratory testing.
Because a single biopsy sample may not capture the most aggressive part of a tumor, surgeons often obtain tissue from multiple regions when possible. As a result, the final grade reflects the most aggressive area found, not simply an average.
- Tissue collection during biopsy or surgical resection
- Histological examination for necrosis, mitotic activity, and vascular changes
- Immunohistochemistry staining to identify specific proteins
- Molecular sequencing for IDH mutation, MGMT methylation, and other markers
The 2021 Update: Molecular Reclassification
One of the most significant WHO CNS5 changes allows a tumor to receive a Grade 4 glioblastoma diagnosis even without classic necrosis or microvascular proliferation. This happens whenever specific molecular markers are present instead. Consequently, this change matters because it catches aggressive tumors earlier, before they develop the most obvious microscopic features.
An IDH-wildtype astrocytoma now qualifies as glioblastoma, Grade 4, if it shows any one of the following genetic changes, even without classic histological necrosis.
- TERT promoter mutation
- EGFR gene amplification
- Combined whole chromosome 7 gain and chromosome 10 loss
This molecular approach also clarified an important distinction. Namely, it separates IDH-wildtype glioblastoma from IDH-mutant astrocytoma, which receives a different grade and behaves quite differently in the clinic. Our detailed comparison of IDH-mutant versus IDH-wildtype glioblastoma explains why this single genetic test changes both diagnosis and expected outcome so significantly.
How Lower-Grade Gliomas Can Become Glioblastoma
Some glioblastomas do not arise suddenly. Instead, they develop from a lower-grade glioma that slowly accumulates additional genetic mutations over months or years. Doctors call this process malignant transformation, and it typically converts a Grade 2 or Grade 3 tumor into a Grade 4 glioblastoma.
This pathway differs meaningfully from recurrence after treatment. Specifically, transformation describes a tumor’s genetic evolution over time, whereas recurrence describes regrowth after therapy. Our separate guide to glioblastoma recurrence, signs, causes, and next steps addresses the regrowth scenario in full detail.
- Primary glioblastoma: arises directly as Grade 4, without a lower-grade precursor, in roughly 90% of cases
- Secondary glioblastoma: evolves from a previously diagnosed lower-grade glioma, in roughly 10% of cases
- Secondary glioblastoma more often carries an IDH mutation and tends to occur in younger patients
Grade Terminology: Common Points of Confusion
Patients often confuse grade with stage, or assume that similar-sounding names describe the same tumor. Clearing up this terminology helps patients ask better questions during consultations and understand their pathology report more confidently.
- Grade versus stage: grade measures aggressiveness, while stage typically measures spread through the body, and brain tumors are graded rather than staged
- Glioma versus astrocytoma: glioma is a broad category, while astrocytoma is one specific type of glioma arising from astrocyte cells
- Anaplastic versus glioblastoma: anaplastic astrocytoma is Grade 3, one step below glioblastoma’s Grade 4
- Multiforme: an older descriptive term no longer used in current WHO nomenclature
Grade 3 Anaplastic Astrocytoma: The Critical Middle Ground
Grade 3 anaplastic astrocytoma sits directly between low-grade gliomas and glioblastoma. Consequently, it plays a pivotal role in this discussion, since many glioblastomas that form through malignant transformation pass through this stage first.
Anaplastic astrocytoma shows increased cellular proliferation and clear nuclear atypia compared with Grade 2 tumors. However, it still lacks the necrosis and microvascular proliferation that define Grade 4. As a result, doctors monitor these tumors closely, since a meaningful proportion eventually progress to glioblastoma over time.
- Median survival for Grade 3 anaplastic astrocytoma generally exceeds that of Grade 4 glioblastoma
- IDH mutation status again predicts outcome strongly within Grade 3 tumors, just as it does at Grade 4
- Treatment typically combines surgery, radiation, and chemotherapy, similar in structure to glioblastoma protocols
International Second Opinions on Grading and Diagnosis
Because grading now depends on molecular testing as well as microscope review, patients sometimes seek a second neuropathology opinion before finalizing a treatment plan. This step matters especially for international patients, since testing standards and available molecular panels vary between countries.
A thorough second review can confirm the original grade, or occasionally reveal a molecular marker that changes the diagnosis meaningfully. Therefore, patients traveling for treatment should bring original pathology slides, biopsy reports, and any prior molecular testing results to their consultation whenever possible.
- Original pathology slides and blocks, when available
- Written pathology and molecular testing reports
- Prior imaging studies, ideally on disc rather than printed film
For guidance on preparing these records before travel, visit our contact page to arrange a consultation with Prof. Dr. Serdar Baki Albayrak.
Why Grade Matters for Treatment Planning
Grade directly shapes the treatment plan a neurosurgical team recommends. A Grade 1 tumor may only require surgery, whereas Grade 4 glioblastoma almost always requires a combined approach that involves surgery, radiation, and chemotherapy together.
- Grade influences how urgently surgery should occur
- Grade influences whether radiation and chemotherapy follow surgery
- Grade, combined with molecular markers, influences which clinical trials a patient may qualify for
Our treatment approaches overview describes each of these options, including surgical technique, radiation planning, and systemic therapy, in greater depth.
Grade and Prognosis: What the Research Shows
Higher grade generally correlates with a more guarded prognosis. However, grade is only one of several factors doctors weigh together when discussing outlook with a patient. Age, extent of surgical resection, MGMT methylation status, and IDH mutation status all interact with grade to shape an individual patient’s expected course.
Because these factors combine in complex ways, prognosis should never rely on grade alone. Our comprehensive guide to glioblastoma survival rate and prognosis factors walks through how these variables interact and what current research supports.
What to Ask About Your Pathology Report
A pathology report can feel overwhelming, especially since it mixes histology terms with molecular testing results. However, a short list of targeted questions helps patients and families understand exactly where they stand.
- What specific features led to this WHO grade?
- Were IDH mutation and MGMT methylation tested, and what were the results?
- Does the report mention TERT, EGFR, or chromosome 7/10 findings?
- Is this classified as primary or secondary glioblastoma?
- How does this grade and these markers change the recommended treatment plan?
Bringing these questions to a consultation ensures that patients leave with a clear understanding of their diagnosis. Consequently, they can make informed decisions about surgery, adjuvant therapy, and follow-up imaging schedules.
Key Takeaways on Grade and Classification
WHO grade remains the starting point for understanding any brain tumor diagnosis. However, modern neuro-oncology no longer treats grade as a standalone number. Instead, doctors interpret it alongside molecular markers, patient age, and overall health to build a complete picture.
For glioblastoma specifically, this means Grade 4 status alone does not fully describe a patient’s situation. Therefore, a thorough pathology review, paired with IDH and MGMT testing, gives both doctors and patients the clearest possible foundation for planning treatment and discussing realistic expectations together.
Frequently Asked Questions
Why is glioblastoma classified as WHO Grade 4?
Pathologists assign Grade 4 status because glioblastoma shows the most aggressive histological features possible, such as necrosis and microvascular proliferation. Alternatively, it may qualify through specific high-risk molecular markers under the 2021 WHO criteria.
Is Grade 4 the same as Stage 4 cancer?
No, and this distinction matters. Grade describes how aggressive tumor cells look and behave, while stage generally describes how far a cancer has spread through the body. Brain tumors, including glioblastoma, are graded rather than staged, since they rarely spread outside the central nervous system.
Can a tumor change grade over time?
Yes. A lower-grade glioma can transform into a higher-grade tumor, including glioblastoma, as it accumulates additional genetic mutations. This process, known as malignant transformation, differs from recurrence after treatment.
What replaced the term glioblastoma multiforme?
Current WHO terminology simply uses glioblastoma. Doctors dropped the word multiforme, which once described the tumor’s varied microscopic appearance, from official nomenclature, although it still appears in older medical literature.
Does every Grade 4 tumor behave identically?
No, and this is an important nuance. Molecular differences, such as IDH mutation status and MGMT methylation status, significantly affect how a Grade 4 tumor responds to treatment and what outcome a patient can expect.
Who confirms the final WHO grade of a brain tumor?
A neuropathologist confirms the final grade. To do so, they examine tumor tissue obtained during biopsy or surgery, then combine those findings with molecular testing performed in the same laboratory workup.
Can imaging alone determine WHO grade without a biopsy?
No. MRI can strongly suggest a high-grade tumor based on its appearance, but only tissue examination and molecular testing can confirm the exact WHO grade. Therefore, a biopsy or surgical resection remains necessary for a definitive diagnosis.
Medical Disclaimer: This page provides general educational information only. It does not constitute medical advice.
It cannot substitute for professional diagnosis or treatment. Please consult Prof. Dr. Serdar Baki Albayrak or another qualified physician directly regarding any diagnosis or treatment decision. For a personal evaluation, contact our clinic.
Request an Appointment
Do you have questions about your diagnosis or treatment options? Send your details below, and our team will contact you to schedule a consultation.
